Novo Nordisk signs deal with OpenAI to develop new drugs
Tech Xplore - Technology and Engineering news [Unofficial]
April 14, 2026
Danish pharmaceuticals group Novo Nordisk, maker of the popular Ozempic and Wegovy anti-obesity drugs, announced Tuesday a "strategic partnership" with OpenAI to accelerate the development of new medications.
Discussion in the ATmosphere